Updated: January 16, 2026
Caverject Shortage Update: What Patients Need to Know in 2026
Author
Peter Daggett

Summarize with AI
Caverject shortages have been ongoing since 2023. Here's the latest update on supply, what changed in 2025, and what patients should do now in 2026.
If you've been struggling to fill a Caverject prescription over the past few years, you've experienced the downstream effects of a real and documented supply crisis. Here is a timeline of what happened, what changed in 2025, and what the landscape looks like for patients in 2026.
The 2023 Caverject Shortage: What Caused It?
In 2023, Pfizer issued a formal supply alert notifying healthcare providers that Caverject Dual Chamber (alprostadil prefilled syringe) would be facing a stock-out, with replenishment not expected until mid-2024. The 40 mcg vials also faced a separate disruption, estimated to begin around June 2023.
The root cause was unusual: a shortage of a competing company's hormone deficiency medication created unprecedented demand for a different Pfizer drug — one that shared the same manufacturing lines as Caverject. Pfizer was forced to prioritize that essential medicine, pushing Caverject production to the back of the queue.
What Happened After 2023?
Recovery was slow and uneven. Even after mid-2024 arrived, many pharmacies reported inconsistent restocking — some receiving Caverject vials while others remained on back-order. Patients across the country reported having to travel significant distances or switch to compounded Trimix to manage their treatment.
The Major Development of 2025: Pfizer Discontinues Caverject Brand
In July 2025, Pfizer announced the permanent discontinuation of several branded products, including Caverject. Generic equivalents of alprostadil injection (10 mcg and 20 mcg) were released to replace the brand. This marked the end of Caverject as a commercially distributed brand in the U.S. — but it did not mean alprostadil injection was going away.
In March 2025, Meitheal Pharmaceuticals had already launched an Alprostadil Injection, USP product, adding supply capacity to the market. Other manufacturers have also entered the space.
Current Availability Status in 2026
As of 2026, the Caverject brand is no longer available. Generic alprostadil injection is on the market but availability remains inconsistent at the pharmacy level. The transition from a single dominant brand (Pfizer's Caverject) to multiple generic manufacturers takes time to filter through to local pharmacy shelves.
Caverject Impulse (the prefilled syringe version) may still be found at some pharmacies as remaining brand inventory is worked through, but new orders of brand product are no longer available. Edex, made by Endo Inc., remains a commercially available brand of alprostadil injection and may be easier to find than generic versions at some locations.
What Should Patients Do Right Now?
Contact your prescriber: Let them know you've heard that Caverject brand has been discontinued. Ask them to rewrite your prescription for generic alprostadil or Edex if needed.
Ask about Trimix: Compounded Trimix is often more available and can be more effective. Ask your urologist if it is appropriate for your situation.
Expand your pharmacy search: Look beyond your usual chain pharmacy. Specialty and compounding pharmacies are more likely to have alprostadil in stock.
Use medfinder to check local availability: Rather than calling pharmacies yourself, use medfinder to find out which ones near you can fill your prescription.
Looking Ahead: Will Alprostadil Injection Get Easier to Find?
Over time, yes. As multiple generic manufacturers ramp up production and pharmacies establish new ordering relationships, availability of generic alprostadil injection should improve. The market for injectable ED therapy is projected to grow — approximately 322 million men worldwide were expected to have erectile dysfunction by 2025 — which gives manufacturers strong commercial incentive to produce reliable supply.
In the meantime, patients need tools to navigate current availability. medfinder helps you find which pharmacies near you have your medication in stock — saving you time and frustration while supply stabilizes.
For patients considering other options, read our guide on alternatives to Caverject if you can't fill your prescription.
Frequently Asked Questions
The Caverject brand was discontinued by Pfizer in July 2025. Generic alprostadil injection is now available as the replacement. Some Caverject Impulse brand stock may remain at certain pharmacies, but new brand product is no longer being manufactured. Edex is another brand still available.
In 2023, a competitor's hormone deficiency medication shortage created unprecedented demand for another Pfizer product that shared the same manufacturing capacity as Caverject. This forced Pfizer to deprioritize Caverject production, leading to a stock-out of the Dual Chamber product and supply disruptions for the 40 mcg vials.
Yes. Following Pfizer's brand discontinuation in July 2025, generic alprostadil injection (10 mcg and 20 mcg) is now available from multiple manufacturers including Meitheal Pharmaceuticals, which launched its product in March 2025. Ask your pharmacist for generic alprostadil injection as a substitute.
Availability is expected to improve as multiple generic manufacturers ramp up production and pharmacies establish new supply relationships. However, as a specialty injectable medication, alprostadil will not be stocked at every pharmacy — patients may still need to call ahead or use a service like medfinder to locate it locally.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Caverject also looked for:
More about Caverject
37,067 have already found their meds with Medfinder.
Start your search today.





